Has anyone got thyroid cancer from Wegovy? What the evidence actually shows

The misconception worth correcting first: animal data is not the same as human risk

When semaglutide was tested in rats and mice at doses far above the therapeutic range, some animals developed C-cell tumours in the thyroid — a type called medullary thyroid carcinoma. That finding is real, it is disclosed in the product information, and it is the origin of almost every alarmed headline or forum post asking whether Wegovy causes thyroid cancer.

The critical context is that rodent thyroid C-cells carry far more GLP-1 receptors than their human equivalents, and they respond to GLP-1 stimulation with a degree of cellular proliferation that simply has not been replicated in human tissue studies. Regulatory bodies including the MHRA and the European Medicines Agency reviewed this data before licensing semaglutide and concluded that the rodent findings are not considered predictive of human risk at clinical doses. The NHS patient information for semaglutide reflects this assessment.

That is not a reason to dismiss the question. It is a reason to understand it accurately rather than either ignoring it or treating a rat study as a settled verdict about humans.

What the human evidence (and the absence of evidence) actually tells us

Large clinical trials of semaglutide, including the STEP programme involving thousands of adults, did not demonstrate an increased incidence of thyroid cancer compared with placebo. Post-marketing surveillance, which continues globally, has not identified a confirmed causal signal in people.

A 2023 observational study published in medical literature raised questions about GLP-1 medicines and thyroid cancer rates in people with type 2 diabetes, generating considerable press coverage. Regulators reviewed it and noted significant methodological limitations, including the difficulty of separating the effect of the medicine from the underlying diabetes, which itself carries elevated thyroid cancer risk. The MHRA's pharmacovigilance work, to which UK patients can contribute by reporting suspected side effects via the Yellow Card scheme, continues to track this.

The honest position is that long-term data in humans are still accumulating. That uncertainty is different from established harm, but it matters, and it is why the contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN2 exists as an absolute rule in the Wegovy Summary of Product Characteristics.

Who should not take Wegovy because of thyroid risk, and what symptoms warrant prompt attention

The licensed contraindications are clear. Wegovy must not be used by anyone with a personal or family history of medullary thyroid carcinoma, or by anyone diagnosed with Multiple Endocrine Neoplasia type 2. These are not relative cautions to weigh up; they are hard stops, and a thorough prescriber assessment will screen for them before any treatment begins.

Outside those contraindications, thyroid cancer is not listed as a recognised side effect of Wegovy in humans by UK regulators. That said, the following symptoms should prompt urgent medical attention regardless of what medicine you are taking: a new lump or swelling in the neck, a voice that has become persistently hoarse, difficulty swallowing, or shortness of breath. These are not specific to Wegovy, they are general thyroid warning signs that should never be attributed to a medicine and left without investigation.

For a closer look at how semaglutide interacts with the thyroid, including the physiology behind the rodent findings and what is known in humans, our dedicated page covers this in more detail. Anyone with an existing thyroid condition (including hypothyroidism) should read about Wegovy and underactive thyroid before consulting a prescriber.

Talking to a prescriber: what good clinical review looks like here

A question this specific deserves a considered clinical answer, not a form field and an automated result. At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician who will review your thyroid history, and if you want to understand more about whether and how semaglutide affects the thyroid, that background can help you have a more informed conversation before any prescribing decision is made.

If you are already on Wegovy and have developed a concern about thyroid symptoms, contact your prescriber or GP promptly rather than stopping treatment without advice. Abrupt discontinuation has its own considerations and a prescriber should guide that conversation. You can also reach our clinical team directly through our contact page.

For anyone starting from scratch and wanting to understand what Wegovy involves, our full Wegovy guide covers the licensed uses, how treatment works, and what the prescribing process looks like. If you want to explore whether semaglutide is appropriate for your circumstances, including if you are in a situation such as having become pregnant while on Wegovy, checking your eligibility with our prescribers is the right starting point.

One practical note: if treatment is approved and prescribed, the pen arrives the next working day via tracked DPD delivery, in plain packaging, nothing on the box indicates what it contains.